| Long name: |
RANK Primary Polyclonal Antibody |
| Also known as: |
RANK PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
RANK |
| Specificity: |
This is a highly specific antibody against RANK |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Subcellular location: |
Extracellular |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human RANK |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
CD265 is also expressed in dendritic cells, CD265 is widely expressed, Human and murine CD265 share 81% amino acid identity in their extracellular domains, Multiple tumor necrosis factor receptor-associated factors (TRAFs) are involved in the signaling of CD265, RANK and RANK ligand (RANKL) are important regulators of interactions between T cells and dendritic cells, RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, TRANCE (TNF-related activation-induced cytokines, The binding of anti-CD265 to cell surface CD265 triggers signal transduction and induces CD265 mediated bioactivity, The biological functions mediated by RANK include activation of NFkappaB and cjun N-terminal kinase, The soluble form of CD265 is able to block TRANCE induced biological activity, also known as RANK ligand, colon, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis and lymph node organogenesis, liver, osteoprotegerin ligand and osteoclast differentiation factor) is the ligand for CD265, small intestine and adrenal gland, thymus, with highest levels in skeletal muscle, CD265 is a member of the tumor necrosis factor receptor (TNFR) family |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
Activator of NFKB, CD 265, CD265, CD265 antigen, EOF, FEO, NFKB activator, ODFR, OFE, Osteoclast dferentiation factor receptor, PDB 2, RANK receptor, Receptor activator of NF KB, TNFRSF 11A, TNFSF11, TNR11_HUMAN, TRANCE R, mRANK, receptor activator of nuclear factor kappa B, TNFRSF11A |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
RANK |
| Short name: |
RANK Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
RANK (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
11908 |
| Gene: |
TNFRSF11A |
More about : TNFRSF11A |
| Long gene name: |
TNF receptor superfamily member 11a |
| Synonyms gene: |
PDB2 LOH18CR1 |
| Synonyms gene name: |
18, NFKB activator , activator of NFKB Paget disease of bone 2 loss of heterozygosity, chromosomal region 1 tumor necrosis factor receptor superfamily, member 11a, member 11a, tumor necrosis factor receptor superfamily |
| Synonyms: |
RANK CD265 FEO |
| Locus: |
18q21, 33 |
| Discovery year: |
1998-12-04 |
| GenBank acession: |
AF018253 |
| Entrez gene record: |
8792 |
| Pubmed identfication: |
9367155 10615125 |
| Classification: |
CD molecules Tumor necrosis factor receptor superfamily |
| Havana BLAST/BLAT: |
OTTHUMG00000132779 |
| Locus Specific Databases: |
LRG_194 |